The immunoproteasome inhibitor ONX-0914 (129) restored the expression of the target proteins, including BTK, IRAK4, IRF4, NPM1, VAV1, and STAT3, in UBE2Ni-treated AML cells (Figure 5C). This evidence concerns the gene BTK and acute myeloid leukemia.